CN115991777A - 新型抗CD3ε抗体 - Google Patents

新型抗CD3ε抗体 Download PDF

Info

Publication number
CN115991777A
CN115991777A CN202211326811.1A CN202211326811A CN115991777A CN 115991777 A CN115991777 A CN 115991777A CN 202211326811 A CN202211326811 A CN 202211326811A CN 115991777 A CN115991777 A CN 115991777A
Authority
CN
China
Prior art keywords
seq
antibody
antigen
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202211326811.1A
Other languages
English (en)
Chinese (zh)
Inventor
李竞
梅芹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wuxi Biologics Shanghai Co Ltd
Original Assignee
Wuxi Biologics Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuxi Biologics Shanghai Co Ltd filed Critical Wuxi Biologics Shanghai Co Ltd
Publication of CN115991777A publication Critical patent/CN115991777A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202211326811.1A 2017-09-21 2018-09-20 新型抗CD3ε抗体 Pending CN115991777A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2017102622 2017-09-21
CNPCT/CN2017/102622 2017-09-21
CN201880056557.3A CN111108119B (zh) 2017-09-21 2018-09-20 新型抗CD3ε抗体
PCT/CN2018/106618 WO2019057099A1 (en) 2017-09-21 2018-09-20 NOVEL ANTI-CD3EPSILON ANTIBODIES

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880056557.3A Division CN111108119B (zh) 2017-09-21 2018-09-20 新型抗CD3ε抗体

Publications (1)

Publication Number Publication Date
CN115991777A true CN115991777A (zh) 2023-04-21

Family

ID=65811028

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202211326811.1A Pending CN115991777A (zh) 2017-09-21 2018-09-20 新型抗CD3ε抗体
CN201880056557.3A Active CN111108119B (zh) 2017-09-21 2018-09-20 新型抗CD3ε抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880056557.3A Active CN111108119B (zh) 2017-09-21 2018-09-20 新型抗CD3ε抗体

Country Status (18)

Country Link
US (2) US11440962B2 (enExample)
EP (1) EP3684806A4 (enExample)
JP (2) JP7305624B2 (enExample)
KR (2) KR20250046337A (enExample)
CN (2) CN115991777A (enExample)
AU (2) AU2018336519B2 (enExample)
BR (1) BR112020004992A2 (enExample)
CA (1) CA3074130A1 (enExample)
EA (1) EA202090800A1 (enExample)
IL (1) IL273393A (enExample)
MX (1) MX2020003087A (enExample)
MY (1) MY199530A (enExample)
PH (1) PH12020550078A1 (enExample)
SA (2) SA523440043B1 (enExample)
SG (1) SG11202001358RA (enExample)
TW (2) TWI820041B (enExample)
WO (1) WO2019057099A1 (enExample)
ZA (1) ZA202001314B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020003144A (es) 2017-09-22 2020-07-28 Wuxi Biologics Ireland Ltd Nuevos complejos de polipeptidos biespecificos cd3/cd19.
KR102839644B1 (ko) 2017-09-22 2025-07-31 우시 바이올로직스 아일랜드 리미티드 신규한 이중특이적 폴리펩티드 복합체
WO2020247929A1 (en) * 2019-06-07 2020-12-10 Adimab, Llc High affinity anti-cd3 antibodies, and methods for their generation and use
US20230067182A1 (en) * 2019-11-29 2023-03-02 Boe Technology Group Co., Ltd. Data Processing Device and Method, and Computer Readable Storage Medium
CA3175140A1 (en) 2020-03-12 2021-09-16 Immune-Onc Therapeutics, Inc. Novel anti-lilrb4 antibodies and derivative products
KR20230017841A (ko) * 2020-05-27 2023-02-06 얀센 바이오테크 인코포레이티드 Cd3 항원 결합 도메인을 포함하는 단백질 및 이의 용도
US20230279138A1 (en) * 2020-07-27 2023-09-07 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Novel bispecific anti-cd3/cd20 polypeptide complex formulation
US12258406B2 (en) 2021-03-24 2025-03-25 Twist Bioscience Corporation Antibodies that bind CD3 Epsilon
US11795224B2 (en) 2021-03-24 2023-10-24 China Medical University Hospital Anti-T-cell nanobody and nucleic acid encoding sequence thereof, and uses of the same
CN115536740A (zh) * 2021-06-30 2022-12-30 苏州方德门达新药开发有限公司 介导细胞内有效滞留cd3的空间构象表位及其应用
CN115558023A (zh) * 2021-07-02 2023-01-03 安源医药科技（上海）有限公司 抗cd3抗体及其用途
CN118922442A (zh) * 2022-03-14 2024-11-08 成都盛世君联生物技术有限公司 一种抗cd3抗体及其制备方法和用途
CN115286715B (zh) * 2022-05-18 2023-05-23 上海百英生物科技股份有限公司 一种抗cd3的纳米抗体或其抗原结合部分及其制备方法
WO2024092038A2 (en) * 2022-10-25 2024-05-02 Ablexis, Llc Anti-cd3 antibodies
TW202430553A (zh) 2022-11-24 2024-08-01 中國大陸商上海藥明生物技術有限公司 Psma抗體及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1298020A (zh) * 1999-11-30 2001-06-06 中国医学科学院中国协和医科大学血液学研究所血液病医院 抗cd3单克隆抗体重链和轻链可变区基因及其应用
CN1984931A (zh) * 2004-06-03 2007-06-20 诺维莫尼公司 抗－cd3抗体及其使用方法
CN104098698A (zh) * 2013-04-08 2014-10-15 中国人民解放军第二军医大学 一种抗cd3抗体及其制法和应用
CN106029696A (zh) * 2013-12-17 2016-10-12 基因泰克公司 抗cd3抗体及使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020142000A1 (en) * 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
WO2007042261A2 (en) * 2005-10-11 2007-04-19 Micromet Ag Compositions comprising cross-species-specific antibodies and uses thereof
CN103694350B (zh) * 2007-04-03 2018-04-24 安进研发（慕尼黑）股份有限公司 跨物种特异性CD3-ε结合结构域
US20100183615A1 (en) * 2007-04-03 2010-07-22 Micromet Ag Cross-species-specific bispecific binders
EP4180458A1 (en) 2008-10-01 2023-05-17 Amgen Research (Munich) GmbH Cross-species-specific psma x cd3 bispecific single chain antibody
WO2011109588A1 (en) * 2010-03-03 2011-09-09 Health Research Inc. Novel cd3 epsilon immunogens and antibodies
EP3004164A1 (en) * 2013-05-28 2016-04-13 Numab AG Novel antibodies
CN106459201A (zh) * 2014-05-28 2017-02-22 豪夫迈·罗氏有限公司 结合人和食蟹猴CD3ε的抗体
ES2850325T3 (es) * 2014-10-09 2021-08-27 Engmab Sarl Anticuerpos biespecíficos contra CD3epsilon y ROR1
LT3247725T (lt) * 2015-01-23 2020-10-12 Sanofi Anti-cd3 antikūnai, anti-cd123 antikūnai ir bispecifiniai antikūnai, specifiškai surišantys cd3 ir (arba) cd123

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1298020A (zh) * 1999-11-30 2001-06-06 中国医学科学院中国协和医科大学血液学研究所血液病医院 抗cd3单克隆抗体重链和轻链可变区基因及其应用
CN1984931A (zh) * 2004-06-03 2007-06-20 诺维莫尼公司 抗－cd3抗体及其使用方法
CN104098698A (zh) * 2013-04-08 2014-10-15 中国人民解放军第二军医大学 一种抗cd3抗体及其制法和应用
CN106029696A (zh) * 2013-12-17 2016-10-12 基因泰克公司 抗cd3抗体及使用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
袁泉 等: "CD3ε和PMA 对fas 基因转录调控作用的研究", 中国生物化学与分子生物学报, vol. 14, no. 6, 31 December 1998 (1998-12-31), pages 770 - 774 *

Also Published As

Publication number Publication date
AU2018336519A1 (en) 2020-03-05
SA520411577B1 (ar) 2024-02-08
TWI820041B (zh) 2023-11-01
EA202090800A1 (ru) 2020-08-11
TW202428617A (zh) 2024-07-16
AU2025201457A1 (en) 2025-03-20
AU2018336519B2 (en) 2024-12-19
CN111108119B (zh) 2022-11-15
CA3074130A1 (en) 2019-03-28
JP7737193B2 (ja) 2025-09-10
JP2020534830A (ja) 2020-12-03
US12485298B2 (en) 2025-12-02
TW201922787A (zh) 2019-06-16
CN111108119A (zh) 2020-05-05
WO2019057099A1 (en) 2019-03-28
US20230192850A1 (en) 2023-06-22
TWI879275B (zh) 2025-04-01
NZ762170A (en) 2023-10-27
SG11202001358RA (en) 2020-03-30
KR20250046337A (ko) 2025-04-02
MX2020003087A (es) 2020-08-17
EP3684806A4 (en) 2021-09-22
JP7305624B2 (ja) 2023-07-10
SA523440043B1 (ar) 2024-02-08
EP3684806A1 (en) 2020-07-29
PH12020550078A1 (en) 2022-07-18
MY199530A (en) 2023-11-03
BR112020004992A2 (pt) 2020-10-06
IL273393A (en) 2020-05-31
US11440962B2 (en) 2022-09-13
JP2023126851A (ja) 2023-09-12
ZA202001314B (en) 2021-08-25
KR20200055052A (ko) 2020-05-20
KR102785140B1 (ko) 2025-03-25
US20200299384A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
US12485298B2 (en) Anti-CD3epsilon antibodies
CN112218892B (zh) 新型抗ctla-4抗体多肽
US20240052052A1 (en) Novel anti-cd24 antibodies
US20220089758A1 (en) Novel anti-cd40 antibodies
WO2019179434A1 (en) Novel bispecific pd-1/cd47 antibody molecules
JP7438180B2 (ja) 新規抗ｌａｇ－３抗体ポリペプチド
WO2020192709A1 (en) Novel bispecific polypeptide complexes
WO2019179422A1 (en) Novel bispecific pd-1/lag-3 antibody molecules
WO2019179421A1 (en) Novel bispecific pd-1/ctla-4 antibody molecules
CN110305216B (zh) 新型抗tim-3抗体
US12486325B2 (en) Anti-CD3epsilon antibodies
US12202894B2 (en) Anti-TIM-3 antibodies
EA042856B1 (ru) Новые анти-cd3-эпсилон антитела
NZ762170B2 (en) Novel anti-cd3epsilon antibodies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination